Wockhardt makes breakthrough in pneumonia treatment with Nafithromycin WCK 4873
Wockhardt is proud to announce the successful completion of its pivotal Phase 3 pneumonia study involving the macrolide antibiotic Nafithromycin WCK 4873. This significant achievement marks a crucial step forward in the development of effective pneumonia treatments. Comparative Evaluation and Impressive Results: The study compared Nafithromycin, also known as WCK 4873, against the last-line respiratory […]